PMID- 36560499
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221226
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 10
IP  - 12
DP  - 2022 Dec 7
TI  - Adverse Events of COVID-19 Vaccination among the Saudi Population: A Systematic 
      Review and Meta-Analysis.
LID - 10.3390/vaccines10122089 [doi]
LID - 2089
AB  - This systematic review and meta-analysis aimed to synthesize the evidence on the 
      adverse events (AEs) of coronavirus disease 2019 (COVID-19) vaccinations in Saudi 
      Arabia. A computerized search in MEDLINE via PubMed and OVID, Scopus, CENTRAL, 
      and Web of Science was conducted using relevant keywords. The NIH tools were used 
      for the quality assessment. A total of 14 studies (16 reports) were included. The 
      pooled analysis showed that the incidence of AEs post-COVID-19 vaccination was 
      40.4% (95% CI:6.4% to 87%). Compared to the AstraZeneca vaccine, the 
      Pfizer-BioNTech vaccine was associated with a lower risk ratio (RR) of wheezing 
      (RR = 0.04), fever (RR = 0.32), chills (RR = 0.41), headache (RR = 0.47), 
      dizziness (RR = 0.49), and joint pain (RR = 0.51). The Pfizer-BioNTech vaccine 
      was associated with significantly higher RR of general allergic reactions (RR = 
      1.62), dyspnea (RR = 1.68), upper respiratory tract symptoms (RR = 1.71), and 
      lymphadenopathy (RR = 8.32). The current evidence suggests that the incidence of 
      AEs following COVID-19 vaccines is 40%; however, most of these AEs were mild and 
      for a short time. The overall number of participants with AEs was higher in the 
      Pfizer group compared to the AstraZeneca group; however, the AstraZeneca vaccine 
      was associated with a higher RR of several AEs.
FAU - Alhossan, Abdulaziz
AU  - Alhossan A
AD  - Department of Clinical Pharmacy, College of Pharmacy, King Saud University, 
      Riyadh P.O. Box 11451, Saudi Arabia.
FAU - Alsaran, Amjad Khalid
AU  - Alsaran AK
AD  - College of Pharmacy, King Saud University, Riyadh P.O. Box 11451, Saudi Arabia.
FAU - Almahmudi, Afnan Hussain
AU  - Almahmudi AH
AUID- ORCID: 0000-0002-5233-1704
AD  - Faculty of Pharmacy, Umm Al Qura University, Makkah P.O. Box 21955, Saudi Arabia.
FAU - Aljohani, Ziad Saad
AU  - Aljohani ZS
AUID- ORCID: 0000-0003-3099-0810
AD  - Faculty of Pharmacy, University of Hail, Hail P.O. Box 2440, Saudi Arabia.
FAU - Albishi, Mohammed Rajeh
AU  - Albishi MR
AD  - Faculty of Pharmacy, Umm Al Qura University, Makkah P.O. Box 21955, Saudi Arabia.
AD  - Ministry of National Guard Health Affairs (MNGHA), Riyadh P.O. Box 22490, Saudi 
      Arabia.
FAU - Almutairi, Ahoud Khashman
AU  - Almutairi AK
AUID- ORCID: 0000-0003-1020-0666
AD  - College of Pharmacy, Qassim University, Unaizah-Qassim P.O. Box 6699, Saudi 
      Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221207
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC9783010
OTO - NOTNLM
OT  - AstraZeneca
OT  - COVID-19
OT  - Pfizer-BioNTech
OT  - adverse events
OT  - vaccine
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/12/07
CRDT- 2022/12/23 02:04
PHST- 2022/10/17 00:00 [received]
PHST- 2022/11/30 00:00 [revised]
PHST- 2022/12/01 00:00 [accepted]
PHST- 2022/12/23 02:04 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/12/07 00:00 [pmc-release]
AID - vaccines10122089 [pii]
AID - vaccines-10-02089 [pii]
AID - 10.3390/vaccines10122089 [doi]
PST - epublish
SO  - Vaccines (Basel). 2022 Dec 7;10(12):2089. doi: 10.3390/vaccines10122089.